Stowe

Stowe Therapeutics is a private biotechnology company focused on the development of novel small molecule inhibitors for the treatment of cancer. The company's primary research efforts center on targeting Ubiquitin Specific Protease 7 (USP7), a deubiquitinating enzyme that plays a critical role in regulating the stability of key proteins involved in tumor suppression and immune response. By inhibiting USP7, Stowe Therapeutics aims to restore natural tumor-suppressive pathways and enhance the efficacy of existing oncology treatments. The company is currently in the pre-clinical stage, advancing its lead candidates through early-stage validation and optimization.